Document is current

Article History

Received: 17 May 2022

Accepted: 11 November 2022

First Online: 30 November 2022

Competing interests

: T.S. reports support from the Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center Israel, and The American Physicians Fellowship for Medicine in Israel. TS reports no competing non-financial interests. C.D. receives research support (to institution) from Roche/Genentech, PUMA, and Daichii Sankyo and consulting fees/honoraria from Daichii Sankyo, Pfizer, Novartis, Gilead, and Seagen. CD reports no competing non-financial interests. D.Y. reports consulting or advisory roles at Novartis, Biotheranostics, Bristol Myers Squibb, G1 Therapeutics, Athenex, Immunomedics, Sanofi/Aventis, R-Pharm, and Lilly; serves on the Speakers’ Bureaus of Novartis, and Genentech/Roche; receives research funding from Genentech/Roche, Novartis, MedImmune, Lilly, Medivation, Pfizer, Tesaro, Macrogenics, AbbVie, Merck, Clovis Oncology, Amgen, Biomarin, Biothera, Dana-Farber Cancer Institute, Incyte, Innocrin Pharma, Nektar, NSABP Foundation, Odonate Therapeutics and Polyphor; and receives travel/accommodations/other expenses from Novartis and Genentech/Roche. DY reports no competing non-financial interests. S.J.I. reports consulting or advisory roles at Seattle Genetics and Novartis, and receives research funding from Genentech, AbbVie, OncoPep, Merck, AstraZeneca/MedImmune, and Outcomes4Me. SJI reports no competing non-financial interests. V.V. receives honoraria from and serves in consulting or advisory roles for Genentech/Roche, Merck, and Novartis; and receives travel/accommodations/other expenses from Genentech/Roche. VV reports no competing non-financial interests. E.P.W. served over the past three years as a consultant to and received honoraria from Carrick Therapeutics, Genentech/Roche, and Jounce Therapeutics. He is an uncompensated member of the Scientific Advisory Boards for Leap Therapeutics. EPW reports no other competing financial or non-financial interests. A.C.W. receives research funding from Roche and Pfizer awarded to Johns Hopkins University; has been named as inventor on one or more issued patents or pending patent applications related to methylation in breast cancer, and has assigned his rights to JHU and participates in a royalty sharing agreement with JHU. Open Payments Link: . A.C.W. reports no competing non-financial interests. I.K. receives institutional research support from Genentech/Roche, Macrogenics, and Pfizer; receives fees from Novartis and Merck for Data Monitoring Board participation and receives consulting fees from Bristol Meyers Squibb, Daiichi/Sankyo, Macrogenics, Taiho Oncology, Genentech/Roche, SeaGen, and AstraZeneca. IK reports no competing non-financial interests. S.M.T. serves in a consulting or advisory role for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Chugai Pharmaceuticals, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Bio and Bayer. SMT receives research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Sanofi, Seattle Genetics. SMT declares no competing non-financial interests. The remaining authors declare no relevant conflicts of interest.